Hepatitis B Vaccine
Excerpt
A safe, highly effective, licensed vaccine for the prevention of hepatitis B virus infection is available. Hepatitis B is a common and serious disease with an annual incidence in the United States of 200 000 cases. Seventy-five percent of patients with hepatitis B have mild or subclinical disease, 25% develop jaundice, 5% require hospitalization, and 0.1% die of fulminant disease; 6% to 10% of infected patients become chronic carriers. Of the 600 000 to 800 000 carriers in the United States, approximately 25% develop chronic hepatitis and approximately 4000 die of cirrhosis each year. In addition, 1% to 2% of
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
ACKNOWLEDGMENTS: The Clinical Efficacy Assessment Project (CEAP) of the American College of Physicians is designed to evaluate and inform College members and others about the safety and efficacy of diagnostic and therapeutic modalities. Evaluation of technologies begins with a notice in Annals of Internal Medicine and the ACP Observer inviting comments. Appropriate members of the Council of Medical Societies and the Council of Subspecialty Societies as well as other experts are asked to review technologies. The CEAP statements thus represent a synthesis of the literature and expert opinion and are intended to reflect the current state-of-the-art knowledge concerning a technology. Statements may be reconsidered as new information becomes available.
Article and Author Information
-
↵* This paper was authored by J. Sanford Schwartz, M.D., and developed for the Health and Public Policy Committee by the Clinical Efficacy Assessment Subcommittee: Donald E. Olson, M.D., Chairman; David Banta, M. D.; Alvan R. Feinstein, M.D.; Howard S. Frazier, M.D.; Richard B. Hornick, M.D.; and Seymour Perry, M.D. Members of the Health and Public Policy Committee for the 1983-1984 term were Edwin P. Maynard, III, M.D., Chairman; Arthur J. Atkinson, Jr., M.D.; Steven C. Beering, M.D.; Richard G. Farmer, M.D.; Paul F. Griner, M.D.; John R. Hogness, M.D.; Charles E. Lewis, M.D.; Donald E. Olson, M.D.; Malcolm L. Peterson, M.D.; Theodore B. Schwartz, M.D.; and Helen L. Smits, M.D. Richard J. Reitemeier, M.D., and Francis J. Sweeney, Jr., M.D., were ex officio members. This position paper was adopted by the Executive Committee of the Board of Regents on 28 September 1983.
-
Grant support: The Clinical Efficacy Assessment Project is funded by the John A. Hartford Foundation.
-
Quotations in advertisements and other commercial publications of text in the American College of Physicians position papers and Clinical Efficacy Assessment Project recommendations must be with express permission from the Department of Health and Public Policy, American College of Physicians, 4200 Pine Street, Philadelphia, PA 19104.
-
▸Requests for reprints should be sent to Linda Johnson White; Clinical Efficacy Assessment Project, Department of Health and Public Policy, American College of Physicians, 4200 Pine Street; Philadelphia, PA 19104.
- © 1984 American College of Physicians
Most Read
